{"prompt": "['Novartis', 'Confidential', 'Page 52', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '6.5.1', 'Physical examination', 'A complete physical examination will be performed at visits specified in the table of', 'assessments (Table 6-1). It will include the examination of general appearance, skin, neck', '(including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes,', 'extremities, vascular and neurological. If indicated based on medical history and/or symptoms,', 'rectal, external genitalia, breast, and pelvic exams will be performed.', 'Abbreviated physical examinations will be performed at visits as indicated in Table 6-1.', 'These will include the examination of the lungs and heart.', 'Information for all physical examinations must be included in the source documentation at the', 'study site. Significant findings that are present prior to informed consent being granted must', 'be included in the Relevant Medical History/Current Medical Conditions screen on the', \"patient's eCRF. Significant findings made after informed consent is given which meet the\", \"definition of an Adverse Event must be recorded on the Adverse Event screen of the patient's\", 'eCRF.', '6.5.2', 'Vital signs', 'Vital signs will be performed at visits specified in the table of assessments (Table 6-1).', 'Measurements will include systolic and diastolic blood pressure, pulse rate, and body', 'temperature.', '6.5.3', 'Height and weight', 'Height in centimeters (cm) will be measured at the visits specified in the table of assessments', '(See Table 6-1).', 'Body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be', 'measured at the visits specified in the table of assessments (See Table 6-1).', 'Body Mass Index (BMI) will be calculated as the weight in kg divided by the height in meters', 'squared.', '6.5.4', 'Laboratory evaluations', 'A central laboratory will be used for analysis of all specimens detailed in this section. Details', 'on the collections, shipment of samples and reporting of results by the central laboratory are', 'provided to investigators in the laboratory manual.', 'Clinically notable laboratory findings are defined in Appendix 1.', '6.5.4.1', 'Hematology', 'Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and', 'platelet count will be measured according to the assessment schedule in Table 6-1. Other', 'reflex testing will be performed as outlined in the laboratory manual.']['Novartis', 'Confidential', 'Page 53', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '6.5.4.2', 'Clinical chemistry', 'BUN/urea, creatinine, creatine kinase, total bilirubin, AST, ALT, alkaline phosphatase,', 'gamma-glutamyl transpeptidase, lactate dehydrogenase, sodium, potassium, chloride, calcium,', 'magnesium, iron, bicarbonate, cholesterol, triglycerides, high-sensitivity C-reactive protein,', 'phosphorus, total protein, albumin, glucose, uric acid, amylase, lipase, CK-MB and Troponin-', 'I (in response to CK results outside of the normal range), HbA1c (collected at Visit 1 only)', 'RAST/ImmunoCAP test), will be measured according to the', 'assessment schedule (Table 6-1). Other reflex testing will be performed as outlined in the', 'laboratory manual.', 'If the total bilirubin concentration is increased above 1.5 times the upper limit of normal range,', 'the total bilirubin will differentiated into the direct and indirect reacting bilirubin.', 'All patients with laboratory tests containing clinically significant abnormalities must be', 'followed until the values return to within the normal ranges or until a clinical explanation is', 'identified, even after study drug has discontinued.', '6.5.4.3 Urinalysis', 'Urine for urinalysis and urine chemistry will be collected according to the collection schedule', 'in Table 6-1. All samples for urinalysis and urine chemistry will be sent to the central', 'laboratory for analysis. The urinalysis evaluation by the central laboratory will include a', 'urine dipstick for specific gravity, protein, glucose, leukocytes and blood and, if required, a', 'microscopic examination. Urine chemistry and microscopic examination of the urine will be', 'performed by the central laboratory as delineated in Table 15-1 \"Specific Renal Alert Criteria', 'and Actions\" in Section 7.4 \"Renal Safety Monitoring\" of this protocol\". Other reflex testing', 'will be performed as outlined in the laboratory manual.', '6.5.5', 'Electrocardiogram (ECG)', 'ECGs will be measured according to the assessment schedule in Table 6-1. At Visit 1, an', 'ECG will be measured to test for eligibility for trial inclusion.', 'ECGs must be recorded according to the ECG investigator manual in the supine position to', 'ensure a stable baseline. The preferred sequence of cardiovascular data collection during study', 'visits is PRO collection first, followed by ECG, and then other study procedures (see Section', '6). The Fridericia QT correction formula (QTcF) must be used for clinical decisions.', 'Single 12 lead ECGs are to be collected with ECG machines supplied by the core laboratory.', 'Full details of all procedures relating to the ECG collection and reporting will be contained in', 'an investigator manual to be provided to each investigator site.', 'The original trace will be sent electronically for central review directly from the ECG', \"machine. Two 'identical' duplicate print-outs will be generated and kept at the investigator\", 'site as source documentation and as back-up for submission to the central laboratory in case', 'of problems with the electronic transmission. Each page of the ECG tracing must be labeled', 'with study number (CQAW039A2317), subject initials (where this is allowed according to', 'local regulations), subject number, date and time, and filed in the study site source documents.']\n\n###\n\n", "completion": "END"}